Literature DB >> 18310910

Madecassoside reduces ischemia-reperfusion injury on regional ischemia induced heart infarction in rat.

Guang-Xing Bian1, Gui-Gui Li, Yun Yang, Rui-Ting Liu, Jian-Ping Ren, Li-Qing Wen, Shao-Ming Guo, Qiu-Jun Lu.   

Abstract

Madecassoside (MA), one of the principle terpenoids in Centella asiatica, has shown protect effect on isolated rat hearts and isolated cardiomyocytes against reperfusion injury in our previous studies. The aim of this study is to investigate if MA also protected against myocardial ischemia-reperfusion injury in vivo. The ischemia infarction model was established in rats. Left ventricular function was monitored during the ischemia-reperfusion period by a multi-channel recorder. After the ischemia-reperfusion process the infarcted areas were assessed. The levels of lactate dehydrogenase (LDH), creatinephosphokinase (CK), malondialdehyde (MDA), super-oxide dismutase (SOD) and C-reactive protein (CRP) in serum were determined. Cardiomyocytic apoptosis was measured by terminal-deoxynucleotidyl transferase mediated nick end labeling (TUNEL) staining. Pre-treatment with MA (50, 10 mg/kg) attenuated myocardial damage characteristic of decreasing infarct size, decreasing LDH and CK release. Activities of SOD were increased and MDA level increased obviously in control group whereas pretreatment with MA blunted the decrease of SOD activity, markedly reduced the level of MDA and the activity of CRP, and relieved myocardial cell apoptosis. These results suggest that MA has the protective effect on myocardial ischemia-reperfusion injury. This protection ability possibly due to its anti-lipid peroxidation, anti-inflammation and anti-apoptosis function and the enhancement of SOD activity.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18310910     DOI: 10.1248/bpb.31.458

Source DB:  PubMed          Journal:  Biol Pharm Bull        ISSN: 0918-6158            Impact factor:   2.233


  5 in total

1.  Alstonia scholaris R. Br. Significantly Inhibits Retinoid-Induced Skin Irritation In Vitro and In Vivo.

Authors:  Soo-Jin Lee; Sun-A Cho; Su-Sun An; Yong-Joo Na; Nok-Hyun Park; Han-Sung Kim; Chan-Woo Lee; Han-Kon Kim; Eun-Kyung Kim; Young-Pyo Jang; Jin-Woong Kim
Journal:  Evid Based Complement Alternat Med       Date:  2011-09-08       Impact factor: 2.629

2.  DIOL triterpenes block profibrotic effects of angiotensin II and protect from cardiac hypertrophy.

Authors:  Ruben Martín; Maria Miana; Raquel Jurado-López; Ernesto Martínez-Martínez; Nieves Gómez-Hurtado; Carmen Delgado; Maria Visitación Bartolomé; José Alberto San Román; Claudia Cordova; Vicente Lahera; Maria Luisa Nieto; Victoria Cachofeiro
Journal:  PLoS One       Date:  2012-07-23       Impact factor: 3.240

3.  Protective effects of madecassoside against Doxorubicin induced nephrotoxicity in vivo and in vitro.

Authors:  Zhonghao Su; Jin Ye; Zhenxia Qin; Xianting Ding
Journal:  Sci Rep       Date:  2015-12-14       Impact factor: 4.379

4.  The baseline levels and risk factors for high-sensitive C-reactive protein in Chinese healthy population.

Authors:  Ying Tang; Peifen Liang; Junzhe Chen; Sha Fu; Bo Liu; Min Feng; Baojuan Lin; Ben Lee; Anping Xu; Hui Y Lan
Journal:  Immun Ageing       Date:  2018-09-08       Impact factor: 6.400

5.  Madecassoside inhibits estrogen deficiency-induced osteoporosis by suppressing RANKL-induced osteoclastogenesis.

Authors:  Qingqing Wang; Lingya Yao; Ke Xu; Haiming Jin; Kai Chen; Ziyi Wang; Qian Liu; Zhen Cao; Jacob Kenny; Yuhao Liu; Jennifer Tickner; Huazi Xu; Jiake Xu
Journal:  J Cell Mol Med       Date:  2018-10-19       Impact factor: 5.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.